JP2024112859A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024112859A5 JP2024112859A5 JP2024077300A JP2024077300A JP2024112859A5 JP 2024112859 A5 JP2024112859 A5 JP 2024112859A5 JP 2024077300 A JP2024077300 A JP 2024077300A JP 2024077300 A JP2024077300 A JP 2024077300A JP 2024112859 A5 JP2024112859 A5 JP 2024112859A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- months
- seq
- determined
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 75
- 230000007423 decrease Effects 0.000 claims 22
- 239000000902 placebo Substances 0.000 claims 19
- 229940068196 placebo Drugs 0.000 claims 19
- 238000009115 maintenance therapy Methods 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 208000024827 Alzheimer disease Diseases 0.000 claims 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 6
- 206010072599 Amyloid related imaging abnormalities Diseases 0.000 claims 4
- 102000001775 Neurogranin Human genes 0.000 claims 4
- 108010015301 Neurogranin Proteins 0.000 claims 4
- 230000037396 body weight Effects 0.000 claims 4
- 210000004556 brain Anatomy 0.000 claims 3
- 230000000007 visual effect Effects 0.000 claims 3
- 108010060159 Apolipoprotein E4 Proteins 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 238000002203 pretreatment Methods 0.000 claims 2
- 108700028369 Alleles Proteins 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 238000004448 titration Methods 0.000 claims 1
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862702659P | 2018-07-24 | 2018-07-24 | |
| US62/702,659 | 2018-07-24 | ||
| US201862749614P | 2018-10-23 | 2018-10-23 | |
| US62/749,614 | 2018-10-23 | ||
| US201962824162P | 2019-03-26 | 2019-03-26 | |
| US62/824,162 | 2019-03-26 | ||
| US201962846902P | 2019-05-13 | 2019-05-13 | |
| US62/846,902 | 2019-05-13 | ||
| US201962874684P | 2019-07-16 | 2019-07-16 | |
| US62/874,684 | 2019-07-16 | ||
| JP2021503770A JP7541505B2 (ja) | 2018-07-24 | 2019-07-23 | アルツハイマー病の治療及び予防方法 |
| PCT/US2019/043067 WO2020023530A2 (en) | 2018-07-24 | 2019-07-23 | Methods of treatment and prevention of alzheimer's disease |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021503770A Division JP7541505B2 (ja) | 2018-07-24 | 2019-07-23 | アルツハイマー病の治療及び予防方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024112859A JP2024112859A (ja) | 2024-08-21 |
| JP2024112859A5 true JP2024112859A5 (enExample) | 2025-03-06 |
Family
ID=67551415
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021503770A Active JP7541505B2 (ja) | 2018-07-24 | 2019-07-23 | アルツハイマー病の治療及び予防方法 |
| JP2024077300A Pending JP2024112859A (ja) | 2018-07-24 | 2024-05-10 | アルツハイマー病の治療及び予防方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021503770A Active JP7541505B2 (ja) | 2018-07-24 | 2019-07-23 | アルツハイマー病の治療及び予防方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210324056A1 (enExample) |
| EP (1) | EP3826674A2 (enExample) |
| JP (2) | JP7541505B2 (enExample) |
| KR (1) | KR20210039402A (enExample) |
| CN (2) | CN112805031A (enExample) |
| AU (1) | AU2019309938A1 (enExample) |
| BR (1) | BR112021001272A2 (enExample) |
| CA (1) | CA3107370A1 (enExample) |
| IL (3) | IL280315B2 (enExample) |
| MX (1) | MX2021000778A (enExample) |
| PH (1) | PH12021500006A1 (enExample) |
| TW (1) | TW202019471A (enExample) |
| WO (1) | WO2020023530A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| PH12022552172A1 (en) * | 2020-03-20 | 2023-12-11 | Eisai R&D Man Co Ltd | High concentration anti-aã protofibril antibody formulations and methods of use thereof |
| US12281166B2 (en) | 2020-05-26 | 2025-04-22 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking Galectin-3 |
| JP2023535024A (ja) | 2020-07-23 | 2023-08-15 | オター プロシーナ リミテッド | 抗ａベータ抗体 |
| US20230302009A1 (en) * | 2020-08-12 | 2023-09-28 | The Cleveland Clinic Foundation | Bace1 inhibitor treatment for suppressing cytokine storm |
| TW202300517A (zh) * | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| US20250051427A1 (en) * | 2021-12-17 | 2025-02-13 | Eisai R&D Management Co., Ltd. | Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody |
| WO2023111618A1 (en) * | 2021-12-17 | 2023-06-22 | Eisai R&D Management Co., Ltd. | Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody |
| KR20240142535A (ko) * | 2022-02-02 | 2024-09-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | P-tau181 수준을 사용한 치료 방법 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001268005A1 (en) | 2000-07-07 | 2002-01-21 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| BRPI0709050B1 (pt) * | 2006-03-23 | 2018-12-26 | Bioarctic Neuroscience Ab | anticorpo ou fragmento do mesmo, composição, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo |
| AU2016208353B2 (en) * | 2007-10-17 | 2017-07-20 | Janssen Alzheimer Immunotherapy | Immunotherapy regimes dependent on ApoE status |
| JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| US20100317850A1 (en) | 2008-01-18 | 2010-12-16 | Yuichi Suzuki | Condensed aminodihydrothiazine derivative |
| PT2448968T (pt) | 2009-06-29 | 2021-04-30 | Bioarctic Ab | ANTICORPOS SELETIVOS PARA PROTOFIBRILAS/OLIGÓMEROS DE ß- AMILOIDE TRUNCADA EM N-TERMINAL |
| EP2538982A4 (en) * | 2010-02-25 | 2016-02-17 | Janssen Alzheimer Immunotherap | PET MONITORING OF IMMUNOTHERAPY TARGETED ON A-BETA |
| JP5894939B2 (ja) | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
| SG191710A1 (en) | 2011-01-21 | 2013-08-30 | Eisai R&D Man Co Ltd | Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives |
| SI3166970T1 (sl) | 2014-07-10 | 2021-09-30 | Bioarctic Ab | Izboljšana A-beta protofibril vezavna protitelesa |
| MA41115A (fr) * | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| CN114019170A (zh) * | 2016-01-20 | 2022-02-08 | 基因泰克公司 | 用于阿尔茨海默氏病的高剂量治疗 |
| WO2017194789A1 (en) * | 2016-05-13 | 2017-11-16 | Institut Pasteur | Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology |
| TWI735600B (zh) * | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| IL316169A (en) | 2016-10-27 | 2024-12-01 | Eisai R&D Man Co Ltd | Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease |
-
2019
- 2019-07-23 CA CA3107370A patent/CA3107370A1/en active Pending
- 2019-07-23 CN CN201980062781.8A patent/CN112805031A/zh active Pending
- 2019-07-23 CN CN202411217698.2A patent/CN118924896A/zh active Pending
- 2019-07-23 KR KR1020217005322A patent/KR20210039402A/ko not_active Ceased
- 2019-07-23 US US17/250,448 patent/US20210324056A1/en active Pending
- 2019-07-23 IL IL280315A patent/IL280315B2/en unknown
- 2019-07-23 EP EP19750196.8A patent/EP3826674A2/en active Pending
- 2019-07-23 BR BR112021001272-9A patent/BR112021001272A2/pt unknown
- 2019-07-23 MX MX2021000778A patent/MX2021000778A/es unknown
- 2019-07-23 WO PCT/US2019/043067 patent/WO2020023530A2/en not_active Ceased
- 2019-07-23 JP JP2021503770A patent/JP7541505B2/ja active Active
- 2019-07-23 AU AU2019309938A patent/AU2019309938A1/en active Pending
- 2019-07-24 TW TW108126224A patent/TW202019471A/zh unknown
-
2021
- 2021-01-21 PH PH12021500006A patent/PH12021500006A1/en unknown
-
2024
- 2024-01-14 IL IL310132A patent/IL310132B1/en unknown
- 2024-05-10 JP JP2024077300A patent/JP2024112859A/ja active Pending
-
2025
- 2025-09-25 IL IL323583A patent/IL323583A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024112859A5 (enExample) | ||
| Yang et al. | Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder | |
| JP2020002171A5 (enExample) | ||
| JP2022033868A5 (enExample) | ||
| JP7541505B2 (ja) | アルツハイマー病の治療及び予防方法 | |
| RU2005127429A (ru) | Активная иммунизация для создания антител к растворимому а-бета | |
| JPH08511005A (ja) | 神経疾患の治療におけるアルカリ性または酸性ホスファターゼインヒビター | |
| JP2021502349A5 (enExample) | ||
| JP2022121658A (ja) | アミロイドーシスを処置するための組成物 | |
| JP2020502261A5 (enExample) | ||
| JP2020535149A5 (enExample) | ||
| CN110891586A (zh) | 用于疗法中的s-亚硝基谷胱甘肽(gsno)和gsno还原酶抑制剂 | |
| JPWO2020023530A5 (enExample) | ||
| US10786557B2 (en) | Compositions and methods useful for the treatment of neuromyelitis optica spectrum disorders | |
| US20240158486A1 (en) | ANTI-N3pGlu AMYLOID BETA ANTIBODIES AND USES THEREOF | |
| US20250377367A1 (en) | Methods of treatment using p-tau181 level | |
| JPWO2020186132A5 (enExample) | ||
| JPWO2023034230A5 (enExample) | ||
| NZ812760B2 (en) | Methods of treatment and prevention of alzheimer's disease | |
| NZ812760A (en) | Methods of treatment and prevention of alzheimer’s disease | |
| RU2832167C2 (ru) | Способы лечения и предупреждения болезни альцгеймера | |
| JPWO2022006283A5 (enExample) | ||
| JPWO2023081194A5 (enExample) | ||
| JPWO2019215701A5 (enExample) | ||
| WO2016189491A1 (en) | Novel formulation |